Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 26, 2007

ChemDiv, Kaken Pharmaceutical Ink Drug Discovery Deal

  • ChemDiv and Kaken Pharmaceutical  entered into a joint drug discovery collaboration involving undisclosed therapeutic targets. ChemDiv is to produce lead candidates employing its discovery outSource™ platform, including proprietary rational design, extensive medicinal chemistry, and preclinical biology capabilities. The designed chemical libraries will be screened at ChemDiv on Kaken's drug targets with a subsequent lead optimization effort.

    Dr. Motoyuki Yajima, Ph.D., executive managing director of research and development of Kaken reports: "We are delighted to be able to work with ChemDiv, as this collaboration combines the complementary skills of both companies to create new compounds for our innovative targets. We are optimistic and happy to have found such a capable partner in ChemDiv."

    Ilya Okun, Ph.D., vp of biology and CTO of ChemDiv, says, "We established and partnered a turnkey lead discovery platform based on ChemDiv's preclinical development services. It included assay development and validation, screening and lead candidate characterization in secondary assays, animal efficacy models, PK, and Tox. We are proud to further expand our successful collaboration with Kaken."

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »